 Toshitaka Sugawara
Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2026 | 928 | 4.620 |
Why?
| | Carcinoma, Pancreatic Ductal | 8 | 2025 | 293 | 2.490 |
Why?
| | Adenocarcinoma | 8 | 2026 | 925 | 2.100 |
Why?
| | Pancreatectomy | 12 | 2026 | 289 | 1.660 |
Why?
| | Neoadjuvant Therapy | 9 | 2026 | 465 | 1.120 |
Why?
| | Hepatectomy | 7 | 2026 | 274 | 1.020 |
Why?
| | CA-19-9 Antigen | 2 | 2024 | 34 | 1.010 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2025 | 76 | 0.920 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2026 | 423 | 0.770 |
Why?
| | Liver Neoplasms | 9 | 2026 | 776 | 0.760 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 36 | 0.750 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 119 | 0.670 |
Why?
| | Databases, Factual | 4 | 2025 | 1490 | 0.650 |
Why?
| | Organ Transplantation | 1 | 2023 | 251 | 0.600 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2024 | 28 | 0.570 |
Why?
| | Biliary Fistula | 1 | 2017 | 4 | 0.540 |
Why?
| | Bile | 1 | 2017 | 26 | 0.530 |
Why?
| | Body Fluids | 1 | 2017 | 71 | 0.510 |
Why?
| | Bilirubin | 1 | 2017 | 99 | 0.510 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2019 | 372 | 0.510 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2026 | 1963 | 0.460 |
Why?
| | Retrospective Studies | 19 | 2026 | 17291 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2025 | 1149 | 0.420 |
Why?
| | Middle Aged | 24 | 2026 | 36215 | 0.370 |
Why?
| | Neoplasm Staging | 4 | 2025 | 1471 | 0.350 |
Why?
| | Aged | 22 | 2026 | 26153 | 0.350 |
Why?
| | Prognosis | 11 | 2024 | 4316 | 0.340 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1327 | 0.280 |
Why?
| | Male | 25 | 2026 | 72842 | 0.270 |
Why?
| | Humans | 33 | 2026 | 145474 | 0.260 |
Why?
| | Survival Rate | 8 | 2024 | 2090 | 0.250 |
Why?
| | Echinocandins | 1 | 2026 | 8 | 0.240 |
Why?
| | Fungemia | 1 | 2026 | 10 | 0.240 |
Why?
| | Cohort Studies | 5 | 2024 | 6013 | 0.240 |
Why?
| | Mesenteric Artery, Superior | 1 | 2026 | 28 | 0.240 |
Why?
| | Saccharomycetales | 1 | 2026 | 29 | 0.230 |
Why?
| | Chyle | 1 | 2025 | 4 | 0.230 |
Why?
| | Colorectal Neoplasms | 3 | 2020 | 866 | 0.230 |
Why?
| | Anastomotic Leak | 1 | 2025 | 45 | 0.230 |
Why?
| | Postoperative Complications | 4 | 2026 | 2970 | 0.230 |
Why?
| | Neutropenia | 1 | 2026 | 154 | 0.220 |
Why?
| | Antifungal Agents | 1 | 2026 | 151 | 0.220 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1321 | 0.220 |
Why?
| | Female | 23 | 2026 | 78844 | 0.220 |
Why?
| | Frozen Sections | 1 | 2025 | 24 | 0.220 |
Why?
| | Diarrhea | 1 | 2026 | 193 | 0.220 |
Why?
| | Organ Sparing Treatments | 1 | 2024 | 37 | 0.210 |
Why?
| | Biliary Tract Neoplasms | 1 | 2024 | 31 | 0.200 |
Why?
| | Aged, 80 and over | 8 | 2025 | 8333 | 0.200 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 331 | 0.200 |
Why?
| | Survival Analysis | 2 | 2024 | 1374 | 0.200 |
Why?
| | Combined Modality Therapy | 2 | 2023 | 1266 | 0.190 |
Why?
| | Preoperative Period | 2 | 2021 | 149 | 0.190 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Robotic Surgical Procedures | 1 | 2026 | 185 | 0.190 |
Why?
| | Area Under Curve | 2 | 2021 | 331 | 0.190 |
Why?
| | ROC Curve | 2 | 2021 | 617 | 0.170 |
Why?
| | Japan | 4 | 2024 | 149 | 0.160 |
Why?
| | Gastroenterology | 1 | 2023 | 191 | 0.160 |
Why?
| | Body Composition | 1 | 2024 | 693 | 0.160 |
Why?
| | Pancreas | 1 | 2023 | 341 | 0.160 |
Why?
| | Lymphocytes | 1 | 2021 | 376 | 0.140 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 184 | 0.140 |
Why?
| | Indocyanine Green | 1 | 2019 | 42 | 0.140 |
Why?
| | Exome | 1 | 2020 | 227 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 969 | 0.140 |
Why?
| | Platelet Count | 1 | 2018 | 94 | 0.140 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 143 | 0.140 |
Why?
| | Cefmetazole | 1 | 2017 | 1 | 0.130 |
Why?
| | Risk Factors | 5 | 2026 | 10885 | 0.130 |
Why?
| | Serum Albumin | 1 | 2018 | 147 | 0.130 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5423 | 0.130 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2018 | 161 | 0.130 |
Why?
| | Adult | 11 | 2025 | 40777 | 0.130 |
Why?
| | Hepatitis B, Chronic | 1 | 2017 | 22 | 0.120 |
Why?
| | Mutation | 2 | 2020 | 4075 | 0.120 |
Why?
| | Drainage | 1 | 2017 | 185 | 0.120 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 134 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 343 | 0.120 |
Why?
| | Viral Load | 1 | 2018 | 526 | 0.110 |
Why?
| | Prevalence | 1 | 2023 | 2865 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1124 | 0.110 |
Why?
| | Hepatitis C | 1 | 2018 | 256 | 0.110 |
Why?
| | Hepatitis C, Chronic | 1 | 2017 | 153 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 254 | 0.110 |
Why?
| | Leucovorin | 2 | 2025 | 98 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2026 | 11772 | 0.100 |
Why?
| | Models, Statistical | 1 | 2018 | 671 | 0.100 |
Why?
| | Fluorouracil | 2 | 2025 | 231 | 0.100 |
Why?
| | Incidence | 3 | 2026 | 2923 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2121 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2664 | 0.080 |
Why?
| | Disease-Free Survival | 2 | 2023 | 767 | 0.070 |
Why?
| | Length of Stay | 2 | 2026 | 1349 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2769 | 0.070 |
Why?
| | Postoperative Period | 2 | 2018 | 351 | 0.060 |
Why?
| | Intention to Treat Analysis | 1 | 2026 | 79 | 0.060 |
Why?
| | Operative Time | 1 | 2026 | 181 | 0.060 |
Why?
| | Catheter-Related Infections | 1 | 2026 | 96 | 0.060 |
Why?
| | Margins of Excision | 1 | 2025 | 50 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2026 | 364 | 0.050 |
Why?
| | Pancreatic Fistula | 1 | 2024 | 35 | 0.050 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 287 | 0.050 |
Why?
| | Republic of Korea | 1 | 2024 | 43 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 206 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 222 | 0.050 |
Why?
| | Forecasting | 1 | 2023 | 390 | 0.040 |
Why?
| | Time Factors | 2 | 2024 | 7123 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 1111 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3413 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 645 | 0.040 |
Why?
| | Prospective Studies | 2 | 2024 | 8057 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3747 | 0.040 |
Why?
| | Ascites | 1 | 2018 | 48 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2019 | 428 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 688 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 205 | 0.030 |
Why?
| | Maryland | 1 | 2017 | 67 | 0.030 |
Why?
| | Hepatitis | 1 | 2017 | 43 | 0.030 |
Why?
| | Hepacivirus | 1 | 2018 | 242 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 506 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 583 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1443 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2017 | 409 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4106 | 0.020 |
Why?
| | Liver | 1 | 2018 | 1896 | 0.020 |
Why?
| | United States | 1 | 2025 | 16098 | 0.020 |
Why?
|
|
Sugawara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|